Eli Lilly finalized a $2.75B deal with Insilico Medicine to commercialize AI-developed drugs, including $115M upfront plus milestones and royalties. Insilico has used generative AI to develop 28+ drugs with nearly half in clinical stages, building on a software licensing partnership that began in 2023.
